Par Historical Income Statement

PAR Stock

288.35 4.15 1.42%

Historical analysis of Par Drugs income statement accounts such as Operating Income of 579.2 M, Ebit of 109.2 M, EBITDA of 142.4 M or Cost Of Revenue of 413.1 M can show how well Par Drugs And performed in making a profits. Evaluating Par Drugs income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Par Drugs's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Par Drugs And latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Par Drugs And is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Par Income Statement Analysis

Par Drugs And Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Par Drugs shareholders. The income statement also shows Par investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Par Drugs Income Statement Chart

At present, Par Drugs' Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Operating Income is expected to grow to about 579.2 M, whereas Total Revenue is forecasted to decline to about 669.2 M.

Total Revenue Gross Profit Other Operating Expenses Income Tax Expense

Total Revenue

Total revenue comprises all receipts Par Drugs And generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Par Drugs And minus its cost of goods sold. It is profit before Par Drugs operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Par Drugs And. It is also known as Par Drugs overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Par Drugs' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Par Drugs And current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Total Revenue	742.0M	951.0M	956.4M	669.2M
Depreciation And Amortization	32.8M	32.3M	34.4M	33.2M

Total Revenue Depreciation And Amortization

Par Drugs income statement Correlations

	Depreciation And Amortization	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Tax Provision	Net Interest Income	Interest Income	Net Income From Continuing Ops	Research Development	Reconciled Depreciation
Depreciation And Amortization		0.85	0.64	0.67	0.73	0.73	0.76	0.75	-0.64	0.81	-0.83	0.8	0.85	-0.8	0.79	0.81	0.78	0.76	0.6	0.74	0.68	0.58
Total Revenue	0.85		0.62	0.82	0.67	0.93	0.93	0.85	-0.48	0.9	-0.85	0.89	0.89	-0.92	0.89	0.88	0.93	0.92	0.59	0.93	0.65	0.39
Gross Profit	0.64	0.62		0.26	0.97	0.66	0.67	0.27	-0.29	0.8	-0.8	0.78	0.83	-0.64	0.59	0.89	0.73	0.67	0.32	0.68	0.95	0.69
Other Operating Expenses	0.67	0.82	0.26		0.31	0.66	0.67	0.97	-0.31	0.7	-0.67	0.7	0.68	-0.82	0.7	0.66	0.65	0.8	0.6	0.69	0.3	0.14
Operating Income	0.73	0.67	0.97	0.31		0.69	0.7	0.37	-0.5	0.85	-0.78	0.83	0.88	-0.7	0.64	0.89	0.74	0.71	0.38	0.71	0.98	0.63
Ebit	0.73	0.93	0.66	0.66	0.69		1.0	0.69	-0.42	0.92	-0.74	0.92	0.9	-0.88	0.8	0.84	0.98	0.89	0.66	0.99	0.67	0.32
Ebitda	0.76	0.93	0.67	0.67	0.7	1.0		0.71	-0.44	0.93	-0.76	0.93	0.91	-0.89	0.81	0.85	0.98	0.9	0.67	0.99	0.68	0.34
Cost Of Revenue	0.75	0.85	0.27	0.97	0.37	0.69	0.71		-0.52	0.74	-0.64	0.74	0.72	-0.85	0.75	0.65	0.67	0.82	0.62	0.72	0.37	0.12
Total Operating Expenses	-0.64	-0.48	-0.29	-0.31	-0.5	-0.42	-0.44	-0.52		-0.52	0.23	-0.52	-0.51	0.49	-0.49	-0.34	-0.36	-0.44	-0.35	-0.42	-0.52	-0.05
Income Before Tax	0.81	0.9	0.8	0.7	0.85	0.92	0.93	0.74	-0.52		-0.81	1.0	0.99	-0.94	0.81	0.94	0.92	0.95	0.69	0.95	0.83	0.4
Total Other Income Expense Net	-0.83	-0.85	-0.8	-0.67	-0.78	-0.74	-0.76	-0.64	0.23	-0.81		-0.79	-0.87	0.77	-0.76	-0.95	-0.84	-0.78	-0.49	-0.75	-0.7	-0.77
Net Income	0.8	0.89	0.78	0.7	0.83	0.92	0.93	0.74	-0.52	1.0	-0.79		0.98	-0.95	0.81	0.92	0.92	0.95	0.69	0.95	0.82	0.36
Income Tax Expense	0.85	0.89	0.83	0.68	0.88	0.9	0.91	0.72	-0.51	0.99	-0.87	0.98		-0.91	0.79	0.96	0.92	0.91	0.66	0.92	0.84	0.52
Interest Expense	-0.8	-0.92	-0.64	-0.82	-0.7	-0.88	-0.89	-0.85	0.49	-0.94	0.77	-0.95	-0.91		-0.9	-0.86	-0.87	-0.99	-0.72	-0.93	-0.69	-0.22
Selling General Administrative	0.79	0.89	0.59	0.7	0.64	0.8	0.81	0.75	-0.49	0.81	-0.76	0.81	0.79	-0.9		0.77	0.81	0.91	0.69	0.83	0.63	0.27
Selling And Marketing Expenses	0.81	0.88	0.89	0.66	0.89	0.84	0.85	0.65	-0.34	0.94	-0.95	0.92	0.96	-0.86	0.77		0.9	0.87	0.52	0.86	0.85	0.64
Tax Provision	0.78	0.93	0.73	0.65	0.74	0.98	0.98	0.67	-0.36	0.92	-0.84	0.92	0.92	-0.87	0.81	0.9		0.88	0.65	0.97	0.7	0.47
Net Interest Income	0.76	0.92	0.67	0.8	0.71	0.89	0.9	0.82	-0.44	0.95	-0.78	0.95	0.91	-0.99	0.91	0.87	0.88		0.71	0.93	0.71	0.23
Interest Income	0.6	0.59	0.32	0.6	0.38	0.66	0.67	0.62	-0.35	0.69	-0.49	0.69	0.66	-0.72	0.69	0.52	0.65	0.71		0.69	0.3	0.12
Net Income From Continuing Ops	0.74	0.93	0.68	0.69	0.71	0.99	0.99	0.72	-0.42	0.95	-0.75	0.95	0.92	-0.93	0.83	0.86	0.97	0.93	0.69		0.7	0.28
Research Development	0.68	0.65	0.95	0.3	0.98	0.67	0.68	0.37	-0.52	0.83	-0.7	0.82	0.84	-0.69	0.63	0.85	0.7	0.71	0.3	0.7		0.52
Reconciled Depreciation	0.58	0.39	0.69	0.14	0.63	0.32	0.34	0.12	-0.05	0.4	-0.77	0.36	0.52	-0.22	0.27	0.64	0.47	0.23	0.12	0.28	0.52

Click cells to compare fundamentals

Par Drugs Account Relationship Matchups

Par Drugs income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	27.6M	28.2M	32.8M	32.3M	34.4M	33.2M
Total Revenue	551.0M	598.8M	742.0M	951.0M	956.4M	669.2M
Gross Profit	154.7M	224.4M	243.4M	286.9M	609.9M	640.4M
Other Operating Expenses	486.4M	467.2M	615.4M	805.4M	404.8M	520.0M
Operating Income	66.9M	131.9M	129.7M	149.7M	551.6M	579.2M
Ebit	67.1M	153.7M	129.7M	149.7M	195.2M	109.2M
Ebitda	94.7M	181.9M	162.5M	182.1M	229.5M	142.4M
Cost Of Revenue	396.3M	374.4M	498.6M	664.0M	346.5M	413.1M
Total Operating Expenses	90.2M	92.8M	116.8M	141.4M	58.3M	77.7M
Income Before Tax	59.9M	147.3M	127.0M	150.8M	195.2M	204.9M
Total Other Income Expense Net	(7.0M)	15.6M	(288.3M)	(346.2M)	(356.4M)	(338.6M)
Net Income	47.6M	116.1M	92.1M	113.3M	145.0M	152.3M
Income Tax Expense	12.3M	31.1M	34.9M	37.5M	50.2M	52.7M
Interest Expense	7.5M	6.0M	3.8M	24K	1.1M	1.0M
Selling General Administrative	12.6M	7.9M	14.6M	12.4M	16.4M	11.4M
Selling And Marketing Expenses	11.8M	21.7M	32.6M	47.6M	53.8M	56.5M
Tax Provision	12.3M	31.1M	34.9M	37.5M	50.2M	29.1M
Net Interest Income	(7.3M)	(6.4M)	(4.5M)	(613K)	(1.1M)	(1.1M)
Interest Income	604.8K	1.3M	1.8M	719K	826.9K	1.1M
Net Income From Continuing Ops	47.6M	116.1M	92.2M	113.3M	145.0M	87.0M
Research Development	666.4K	988K	147.4K	1.0M	3.3M	3.5M
Reconciled Depreciation	27.6M	28.2M	32.8M	32.3M	34.4M	34.1M
Net Income Applicable To Common Shares	25.1M	47.6M	116.1M	92.2M	106.0M	65.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Other Information on Investing in Par Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Par Historical Income Statement

About Par Income Statement Analysis

Par Drugs Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Par Drugs income statement Correlations

Par Drugs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Par Drugs income statement Accounts

Also Currently Popular

Other Information on Investing in Par Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Net Income From Continuing Ops	+ 0.99	Ebit
Net Income From Continuing Ops	+ 0.99	Ebitda
Income Tax Expense	+ 0.99	Income Before Tax
Research Development	+ 0.98	Operating Income

Net Interest Income	- 0.99	Interest Expense
Interest Expense	- 0.95	Net Income
Selling And Marketing Expenses	- 0.95	Total Other Income Expense Net
Interest Expense	- 0.94	Income Before Tax
Net Income From Continuing Ops	- 0.93	Interest Expense
Interest Expense	- 0.92	Total Revenue